Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates
- PMID: 17910277
- DOI: 10.1080/09674845.2007.11732766
Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates
Abstract
The pH at the site of infection is one of a number of factors that may significantly influence the in vivo activity of an antibiotic prescribed for treatment of infection and it may be of particular importance in the treatment of cystic fibrosis (CF) pulmonary infection, as acidification of the airways in CF patients has been reported. As Pseudomonas aeruginosa is the most frequent causative pathogen of CF pulmonary infection, this study determines the effect that growth at a reduced pH, as may be experienced by P. aeruginosa during infection of the CF lung, has on the susceptibility of clinical P. aeruginosa isolates, grown planktonically and as biofilms, to tobramycin and ceftazidime. Time-kill assays revealed a clear loss of tobramycin bactericidal activity when the isolates were grown under acidic conditions. MIC and MBC determinations also showed decreased tobramycin activity under acidic conditions, but this effect was not observed for all isolates tested. In contrast, growth of the isolates at a reduced pH had no adverse effect on the bacteriostatic and bactericidal activity of ceftazidime. When the isolates were grown as biofilms, the pH at which the biofilms were formed did not affect the bactericidal activity of either tobramycin or ceftazidime, with neither antibiotic capable of eradicating biofilms formed by the isolates at each pH. This was in spite of the fact that the concentrations of both antibiotics used were much higher than the concentrations required to kill the isolates growing planktonically. These results show that growth in an acidic environment may reduce the susceptibility of clinical P. aeruginosa isolates to tobramycin.
Similar articles
-
Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.Eur J Clin Microbiol Infect Dis. 2005 Oct;24(10):677-87. doi: 10.1007/s10096-005-0031-9. Eur J Clin Microbiol Infect Dis. 2005. PMID: 16249934
-
Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.J Clin Microbiol. 2005 Oct;43(10):5085-90. doi: 10.1128/JCM.43.10.5085-5090.2005. J Clin Microbiol. 2005. PMID: 16207967 Free PMC article.
-
Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung.J Vis Exp. 2012 Jun 5;(64):e3857. doi: 10.3791/3857. J Vis Exp. 2012. PMID: 22711026 Free PMC article.
-
Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.APMIS Suppl. 2003;(116):1-47. APMIS Suppl. 2003. PMID: 14692154 Review.
-
The Consequences of Being in an Infectious Biofilm: Microenvironmental Conditions Governing Antibiotic Tolerance.Int J Mol Sci. 2017 Dec 12;18(12):2688. doi: 10.3390/ijms18122688. Int J Mol Sci. 2017. PMID: 29231866 Free PMC article. Review.
Cited by
-
The spatial profiles and metabolic capabilities of microbial populations impact the growth of antibiotic-resistant mutants.J R Soc Interface. 2015 Jun 6;12(107):20150018. doi: 10.1098/rsif.2015.0018. J R Soc Interface. 2015. PMID: 25972434 Free PMC article.
-
Antimicrobial peptide glatiramer acetate targets Pseudomonas aeruginosa lipopolysaccharides to breach membranes without altering lipopolysaccharide modification.NPJ Antimicrob Resist. 2024 Feb 20;2(1):4. doi: 10.1038/s44259-024-00022-x. NPJ Antimicrob Resist. 2024. PMID: 39843948 Free PMC article.
-
Physiology of Pseudomonas aeruginosa in biofilms as revealed by transcriptome analysis.BMC Microbiol. 2010 Nov 17;10:294. doi: 10.1186/1471-2180-10-294. BMC Microbiol. 2010. PMID: 21083928 Free PMC article.
-
An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.Antimicrob Agents Chemother. 2017 Nov 22;61(12):e00987-17. doi: 10.1128/AAC.00987-17. Print 2017 Dec. Antimicrob Agents Chemother. 2017. PMID: 28923873 Free PMC article.
-
Heterogeneity in Pseudomonas aeruginosa biofilms includes expression of ribosome hibernation factors in the antibiotic-tolerant subpopulation and hypoxia-induced stress response in the metabolically active population.J Bacteriol. 2012 Apr;194(8):2062-73. doi: 10.1128/JB.00022-12. Epub 2012 Feb 17. J Bacteriol. 2012. PMID: 22343293 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials